of T cells within a specific immune context is fated to change according to the timing of the response and to the establishment of different immune/stroma interfaces. In this setting, a notable example is represented by the induction of tertiary lymphoid structures in tissues of patients with autoimmune diseases or cancer. In this context, the polarization of programmed cell death 1 receptor‐positive (PD1+) Tfh cells from adaptive or tissue‐resident innate‐like T cells [10] is entwined with the formation of a follicular dendritic cell network from vessel‐associated mesenchymal stromal cells (Figure 1.2) [11]. This process leads to the establishment of a specialized stroma‐T‐cell interface that may be either aberrantly expanded or variably disrupted in different lymphoma subtypes related to the germinal center, such as is seen with angioimmunoblastic T‐cell lymphoma [12], and the follicular lymphomas [13], respectively.
Besides primary polarization and conversion dictated by the cytokine milieu and stromal micro niches, an emerging role for TCR specificity in determining fate specification of tissue‐resident T cells at sites of persistent antigenic challenge, such as the intestinal lamina propria, is emerging [14]. Clonal TCR rearrangements of peripheral FOXP3+ Treg (pTreg) promote the generation of distinct pTreg CD4 intraepithelial T‐cell phenotypes, which show comparable dependence on microbiota‐derived antigenic stimuli and different reliance on intraclonal competition. Intraclonal competition driven by TCR‐antigen signaling is a limiting factor in natural and pTreg development, with low clonal precursor frequencies being required for their generation [15].
The specific issue of intraclonal competition and “small niche” requirement as a potential determinant of T‐cell subclones’ fate specification in the presence of self‐ and/or microbiota‐derived antigenic represents a still unchallenged level of complexity in peripheral T‐cell lymphoma (PTCL) research. In this regard, single‐cell RNA sequencing (Sc‐RNA‐seq) provides a dramatically higher level of resolution of the developmental and functional heterogeneity of T‐cell subsets, which is applicable to the PTCL setting.
Sc‐RNA‐seq has provided reference maps for circulating and tissue‐based T cells and their functional hierarchies [16]. Among relevant transcriptional differences between peripheral blood and tissue‐based T cells, cytoskeleton, cell–matrix interaction, and cell proliferation modules have emerged, underscoring the transcriptional imprint of tissue microenvironment. This information must be considered in the interpretation of gene expression profiling studies on PTCL, which have mostly relied on the differential comparison with normal T‐cell subsets from peripheral blood and/or cell lines.
Figure 1.2 Representative immunohistochemical staining for PD1 (upper left) and NGFR/CD271 (upper right) highlighting the presence of PD1+ T follicular helper cells and of a formed meshwork of follicular dendritic cells within a tertiary lymphoid follicle in a case of non‐small‐cell lung carcinoma. Immunohistochemical staining for CD146 (lower left) and CD23 (lower right) highlighting the early branching of perivascular CD146+ mesenchymal elements that partially display CD23 expression as a marker of follicular dendritic cell differentiation in the same non‐small‐cell lung carcinoma.
Source: Claudio Tripodo, Stefano Pilleri.
Moreover, at the Sc‐RNA‐seq level, a clear dichotomy in the CD8+ effector T‐cell cluster emerges as conserved across tissue sites, based on the predominance of cytotoxicity‐related genes or cytokine and chemokine genes [16].
Tissue‐conserved Sc‐RNA‐seq transcriptional clustering also identifies distinct Treg, CD4+ naïve/central memory resting and CD4+/CD8+ resting clusters, IFN response, and proliferation gene clusters characterizing different CD4+ T‐cell activation states [16]. Interestingly, hallmarks of such transcriptional modules feature the concomitant expression of genes coding for transcription factors involved in divergent‐fate specifications (e.g. FOXP3, IRF4, and TOX2), highlighting the dynamical regulation of promiscuous transcription factors [17, 18]. Again, this concept may represent a relevant note of caution in the interpretation of transcription factor expression data in PTCL clonal populations as hallmarks of stable clone differentiative/phenotypic states.
The expression and activity of specific transcription factors involved in fate specification, such as T‐bet and IRF4, is bound to that of the pleiotropic transcription factor MYC in enabling TCR‐driven immune function through the regulation of T‐cell proteomic and metabolic landscape [19]. MYC proficiency has been demonstrated to be required for adapting protein expression to TCR engagement in CD4+ and CD8+ cells. Through the regulation of amino acid transporter expression, MYC impacts on translational activity and on the associated increase of effector T‐cell biomass (Figure 1.3) [19], which relates with the higher Myc expression levels in CD8+ T cells.
Moreover, upon T‐cell activation, MYC controls lactate transporter expression, regulating the feedback on glycolytic flux fueling T‐cell synthetic programs and proliferative attitude [19]. In PTCL‐NOS not otherwise specified, overexpression of MYC and its transcriptional targets involved in cell proliferation has been implicated in the worse prognosis of GATA3‐positive cases [20]. Nevertheless, in the light of the profound effects on the metabolic adaptation to TCR sensing, MYC may represent an underrated determinant of inter/intraclonal competition [21] underlying PTCL progression.
Figure 1.3 The biomass of CD8+ effector T cells is dramatically different between peritumoral (left panel) and intratumoral (right panel) compartments of a high‐grade carcinoma. Intra‐tumoral CD8+ effectors corresponding to an activated state showing a larger size.
Source: Claudio Tripodo, Stefano Pilleri.
This introductory chapter provides an updated view of the mature T‐cell constellation, in a less static view, as compared with canonical ontogeny‐focused outlines, providing information on the biological foundations of functional plasticity, phenotypical heterogeneity, and transcriptional dynamics that are recapitulated and magnified in peripheral T‐cell malignancies. It is imperative to recognize that the diversity, and complex function of normal T cells, is central to appreciating the many histologic and genetic subtypes of PTCL, and may aid in explaining the diverse behavior and presentation of these challenging and heterogeneous diseases.
Must Reads
Litman, G.W., Cannon, J.P., and Dinshaw, L.J.. (2005). Reconstructing immune phylogeny: new perspectives. Nat Rev Immunol 5(11): 866–879.
Restifo, N.P. and Gattinoni, L. (2013). Lineage relationship of effector and memory T‐cell. Curr Opin Immunol 25(5): 556–563.
Withers, D.R. (2016). Innate lymphoid cells regulation of adaptive immunity. Immunology 149(2): 123–130.
References
1 1 Swerdlow, S.H., Campo, E., Harris, N.L. et al. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4e. Lyon: IARC.
2 2 Kanhere, A., Hertweck, A., Bhatia, U. et al. (2012). T‐bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage‐specific targeting of distal regulatory elements. Nat Commun 3: 1268.
3 3 Yang, X.O., Pappu, B.P., Nurieva, R. et al. (2008). T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 28 (1): 29–39.
4 4 Plank, M.W., Kaiko, G.E., Maltby, S. et al. (2017). Th22 cells form a distinct Th lineage from Th17 cells in vitro with unique transcriptional properties and Tbet‐dependent Th1 plasticity. J Immunol 198 (5): 2182–2190.
5 5